Sitagliptin's Safety; New Option Approved for Hospital-Acquired Pneumonia; FDA Approves First Nonhormonal Drug for Menopause Symptoms

In 2007, sitagliptin was the first dipeptidyl peptidase-4 (DPP-4) inhibitor released in the U.S., but research has still not completely captured its benefits and risks. These DPP-4 inhibitors have been shown to modestly improve cardiovascular risk factors, such as triglyceride levels and blood pressure, but data have been inconsistent, say researchers from the University of Alberta in Canada, the University of Illinois College of Medicine in Peoria, and the University of Illinois at Chicago College of Pharmacy.